Steven Fruchtman

Company: Onconova Therapeutics Inc

Job title: President & CEO

Seminars:

Maximizing Anti-Tumor Response: Targeting the RAS/MAPK Pathway Using a RASAgnostic Approach 3:00 pm

Targeting the RAS binding domain with Rigosertib to inhibit binding of multiple downstream proteins in the RAS/MAPK pathway leads to effective cancer treatment Transforming cold tumors to hot tumors with Rigosertib by upregulating neoantigen presentation increases immune system involvement and results in a better anti-cancer response Exploring combinations with Immune Checkpoint Inhibitors (ICIs) offers the…Read more

day: Day One Track B PM